Fingerprint Fingerprint is based on mining the text of the persons scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 4 Similar Profiles
Leukemia, Myelogenous, Chronic, BCR-ABL Positive Medicine & Life Sciences
Philadelphia Chromosome Medicine & Life Sciences
Interferon-alpha Medicine & Life Sciences
Leukemia, Myeloid, Chronic Phase Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Cytogenetics Medicine & Life Sciences
Interferons Medicine & Life Sciences
Leukemia Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 1997 2026

Research Output 1979 2018

Dasatinib dose management for the treatment of chronic myeloid leukemia

Talpaz, M., Saglio, G., Atallah, E. & Rousselot, P. Apr 15 2018 In : Cancer. 124, 8, p. 1660-1672 13 p.

Research output: Contribution to journalReview article

Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Protein-Tyrosine Kinases
Neoplasms
Licensure
Therapeutics

Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG

Scappaticci, G. B., Marini, B. L., Nachar, V. R., Uebel, J. R., Vulaj, V., Crouch, A., Bixby, D. L., Talpaz, M. & Perissinotti, A. J. Apr 1 2018 In : Annals of Hematology. 97, 4, p. 573-584 12 p.

Research output: Contribution to journalArticle

Propensity Score
Acute Myeloid Leukemia
Survival
Anthracyclines
Cytarabine
2 Citations

Pacritinib vs best available therapy, including ruxolitinib, in patients with myelofibrosis: A randomized clinical trial

Mascarenhas, J., Hoffman, R., Talpaz, M., Gerds, A. T., Stein, B., Gupta, V., Szoke, A., Drummond, M., Pristupa, A., Granston, T., Daly, R., Al-Fayoumi, S., Callahan, J. A., Singer, J. W., Gotlib, J., Jamieson, C., Harrison, C., Mesa, R. & Verstovsek, S. May 1 2018 In : JAMA Oncology. 4, 5, p. 652-659 8 p.

Research output: Contribution to journalArticle

Primary Myelofibrosis
Randomized Controlled Trials
Therapeutics
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
INCB018424

Treatment With JAK Inhibitors in Myelofibrosis Patients Nullifies the Prognostic Impact of Unfavorable Cytogenetics

Ma, V. T., Boonstra, P. S., Menghrajani, K., Perkins, C., Gowin, K. L., Mesa, R. A., Gotlib, J. R. & Talpaz, M. May 1 2018 In : Clinical Lymphoma, Myeloma and Leukemia. 18, 5, p. e201-e210

Research output: Contribution to journalArticle

Janus Kinases
Primary Myelofibrosis
Cytogenetics
Survival
Therapeutics

Usp9x Promotes Survival in Human Pancreatic Cancer and Its Inhibition Suppresses Pancreatic Ductal Adenocarcinoma In Vivo Tumor Growth

Pal, A., Dziubinski, M., Di Magliano, M. P., Simeone, D. M., Owens, S., Thomas, D., Peterson, L., Potu, H., Talpaz, M. & Donato, N. J. Feb 1 2018 In : Neoplasia (United States). 20, 2, p. 152-164 13 p.

Research output: Contribution to journalArticle

Pancreatic Neoplasms
Adenocarcinoma
Survival
Growth
Neoplasms